Literature DB >> 22824795

The gain of function of p53 cancer mutant in promoting mammary tumorigenesis.

X Lu1, D P Liu, Y Xu.   

Abstract

Tumor suppressor p53 is critical for suppressing all types of human cancers, including breast cancer. The p53 gene is somatically mutated in over half of all human cancers. The majority of the p53 mutations are missense mutations, leading to the expression of the full-length p53 mutants. Several hotspot mutations, including R175H, are frequently detected in human breast cancer. P53 cancer mutants not only lose tumor suppression activity but, more problematically, also gain new oncogenic activities. Despite correlation of the expression of p53 cancer mutants and the poor prognosis of human breast cancer patients, the roles of p53 cancer mutants in promoting breast cancer remain unclear. We used the humanized p53 cancer mutant knock-in (R175H) mice and mouse mammary tumor virus (MMTV)-Wnt-1 transgenic (mWnt-1) mice to specifically address the gain of function of R175H in promoting breast cancer. Although both R175H/R175HmWnt-1(R175HmWnt-1) and p53(-/-)mWnt-1 mice died from mammary tumor at the same kinetics, which was much earlier than mWnt-1 mice, most of the R175HmWnt-1 mice developed multiple mammary tumors per mouse, whereas p53(-/-)mWnt-1 and mWnt-1 mice mostly developed one tumor per mouse. The multiple mammary tumors arose in the same R175HmWnt-1 mouse exhibited different histological characters. Moreover, R175H gain-of-function mutant expands the mammary epithelial stem cells (MESCs) that give rise to the mammary tumors. As ATM suppresses the expansion of MESCs, the inactivation of ATM by R175H in mammary epithelial cells (MECs) could contribute to the expansion of MESCs in R175HmWnt-1 mice. These findings provide the basis for R175H to promote the initiation of breast cancer by expanding MESCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22824795      PMCID: PMC3586389          DOI: 10.1038/onc.2012.299

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.

Authors:  Gabriela Dontu; Wissam M Abdallah; Jessica M Foley; Kyle W Jackson; Michael F Clarke; Mari J Kawamura; Max S Wicha
Journal:  Genes Dev       Date:  2003-05-15       Impact factor: 11.361

Review 2.  Global cancer statistics in the year 2000.

Authors:  D M Parkin
Journal:  Lancet Oncol       Date:  2001-09       Impact factor: 41.316

3.  Genetic basis for p53 overexpression in human breast cancer.

Authors:  A M Davidoff; P A Humphrey; J D Iglehart; J R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

Review 4.  The p53 tumor suppressor gene in breast cancer.

Authors:  R M Elledge; D C Allred
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 5.  Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens.

Authors:  S P Hussain; C C Harris
Journal:  Mutat Res       Date:  2000-04       Impact factor: 2.433

Review 6.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

7.  Gain of function mutations in p53.

Authors:  D Dittmer; S Pati; G Zambetti; S Chu; A K Teresky; M Moore; C Finlay; A J Levine
Journal:  Nat Genet       Date:  1993-05       Impact factor: 38.330

8.  Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice.

Authors:  A S Tsukamoto; R Grosschedl; R C Guzman; T Parslow; H E Varmus
Journal:  Cell       Date:  1988-11-18       Impact factor: 41.582

Review 9.  Tumour suppression by p53: a role for the DNA damage response?

Authors:  David W Meek
Journal:  Nat Rev Cancer       Date:  2009-09-04       Impact factor: 60.716

10.  Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.

Authors:  Suh-Chin J Lin; Kuo-Fen Lee; Alexander Yu Nikitin; Susan G Hilsenbeck; Robert D Cardiff; Aihua Li; Keon-Wook Kang; Steven A Frank; Wen-Hwa Lee; Eva Y-H P Lee
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

View more
  28 in total

1.  Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer.

Authors:  D Ashikari; K Takayama; T Tanaka; Y Suzuki; D Obinata; T Fujimura; T Urano; S Takahashi; S Inoue
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

Review 2.  Illuminating p53 function in cancer with genetically engineered mouse models.

Authors:  Patty B Garcia; Laura D Attardi
Journal:  Semin Cell Dev Biol       Date:  2014-01-03       Impact factor: 7.727

3.  A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion.

Authors:  Katharine D Grugan; Maria E Vega; Gabrielle S Wong; J Alan Diehl; Adam J Bass; Kwok K Wong; Hiroshi Nakagawa; Anil K Rustgi
Journal:  Cancer Biol Ther       Date:  2013-06-18       Impact factor: 4.742

4.  Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis.

Authors:  Alisha R Yallowitz; Dun Li; Anthony Lobko; Daniel Mott; Alice Nemajerova; Natalia Marchenko
Journal:  Mol Cancer Res       Date:  2015-01-08       Impact factor: 5.852

Review 5.  Molecularly targeted therapies for p53-mutant cancers.

Authors:  Dekuang Zhao; William M Tahaney; Abhijit Mazumdar; Michelle I Savage; Powel H Brown
Journal:  Cell Mol Life Sci       Date:  2017-06-22       Impact factor: 9.261

Review 6.  Is loss of p53 a driver of ductal carcinoma in situ progression?

Authors:  Rhiannon L Morrissey; Alastair M Thompson; Guillermina Lozano
Journal:  Br J Cancer       Date:  2022-06-28       Impact factor: 7.640

7.  Homologs of the Tumor Suppressor Protein p53: A Bioinformatics Study for Drug Design.

Authors:  Kelly M Thayer; Claudia Carcamo
Journal:  MOJ Proteom Bioinform       Date:  2020-02-05

Review 8.  Clinical Outcomes of TP53 Mutations in Cancers.

Authors:  Ana I Robles; Jin Jen; Curtis C Harris
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

Review 9.  The Function of the Mutant p53-R175H in Cancer.

Authors:  Yen-Ting Chiang; Yi-Chung Chien; Yu-Heng Lin; Hui-Hsuan Wu; Dung-Fang Lee; Yung-Luen Yu
Journal:  Cancers (Basel)       Date:  2021-08-13       Impact factor: 6.639

Review 10.  AlphaB-crystallin and breast cancer: role and possible therapeutic strategies.

Authors:  Daniela Caporossi; Attilio Parisi; Cristina Fantini; Elisa Grazioli; Claudia Cerulli; Ivan Dimauro
Journal:  Cell Stress Chaperones       Date:  2020-10-28       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.